Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)

I project 2015 sales of Otrexup at $22 million; if so, it would be generating profit in the latter half of 2015. Antares seems confident that Teva’s generic to EpiPen will be approved in June 2015 and AB rated. On an annualized basis, I see this this generic contributing $25 million pretax by 4Q, 2015. [...]

«Older Posts
«Older Posts
Search Graphic